Relationships between cytoprotection and mutation prevention by WR-1065.

Area of Science:

• Radioprotective agents
• Cancer therapy
• Molecular mechanisms of drug action

Background:

• WR-2721 is the first clinically used cytoprotector in cancer therapy.
• Its active thiol, WR-1065, functions as an antioxidant, scavenging free radicals and donating hydrogen atoms.
• WR-1065 exhibits cytoprotective effects through antioxidant mechanisms.

Purpose of the Study:

• To investigate the multifaceted mechanisms of WR-2721 and its active metabolite WR-1065.
• To explore the effects of WR-1065 at concentrations lower than those required for cytoprotection.
• To differentiate the mechanisms of cytoprotection from those involved in preventing mutagenesis and cancer formation.

Main Methods:

• Investigated the antioxidant properties of WR-1065 (free radical scavenging, hydrogen atom donation).
• Assessed the impact of WR-1065 on gene expression, transcription factor binding (NF-kappa B), and protein phosphorylation at low concentrations.
• Evaluated the effects on mutagenesis and carcinogenic risk reduction.

Main Results:

• WR-1065's antioxidant activity contributes to its cytoprotective effectiveness.
• At lower concentrations, WR-1065 modulates gene expression, activates NF-kappa B binding, and affects protein phosphorylation.
• These low-dose effects differ from the mechanisms of cytoprotection against cell killing.
• WR-1065 influences mutagenesis and may reduce carcinogenic risks.

Conclusions:

• The mechanisms by which WR-2721 protects against cell killing differ from those protecting against mutagenesis and cancer.
• WR-1065's ability to influence gene expression and other cellular processes at low doses is significant.
• WR-2721 is a valuable agent for reducing carcinogenic risks from radiation and chemical exposures.